We also demonstrate that BIRC3 mutation in the remaining allele of del(11q) CLL cells confers clonal advantage which could account for the negative predictive impact of BIRC3 biallelic inactivation in CLL. The gene discussed is BIRC3; the disease is B-cell chronic lymphocytic leukemia.